Characterization of different biocatalyst formats for BVMO-catalyzed cyclohexanone oxidation.
Lisa BretschneiderIngeborg HeuschkelAfaq AhmedKatja BühlerRohan KarandeBruno BühlerPublished in: Biotechnology and bioengineering (2021)
Cyclohexanone monooxygenase (CHMO), a member of the Baeyer-Villiger monooxygenase family, is a versatile biocatalyst that efficiently catalyzes the conversion of cyclic ketones to lactones. In this study, an Acidovorax-derived CHMO gene was expressed in Pseudomonas taiwanensis VLB120. Upon purification, the enzyme was characterized in vitro and shown to feature a broad substrate spectrum and up to 100% conversion in 6 h. Furthermore, we determined and compared the cyclohexanone conversion kinetics for different CHMO-biocatalyst formats, that is, isolated enzyme, suspended whole cells, and biofilms, the latter two based on recombinant CHMO-containing P. taiwanensis VLB120. Biofilms showed less favorable values for KS (9.3-fold higher) and kcat (4.8-fold lower) compared with corresponding KM and kcat values of isolated CHMO, but a favorable KI for cyclohexanone (5.3-fold higher). The unfavorable KS and kcat values are related to mass transfer- and possibly heterogeneity issues and deserve further investigation and engineering, to exploit the high potential of biofilms regarding process stability. Suspended cells showed only 1.8-fold higher KS , but 1.3- and 4.2-fold higher kcat and KI values than isolated CHMO. This together with the efficient NADPH regeneration via glucose metabolism makes this format highly promising from a kinetics perspective.
Keyphrases
- induced apoptosis
- cell cycle arrest
- candida albicans
- stem cells
- machine learning
- endoplasmic reticulum stress
- neoadjuvant chemotherapy
- signaling pathway
- oxidative stress
- escherichia coli
- squamous cell carcinoma
- gene expression
- cell death
- copy number
- lymph node
- radiation therapy
- risk assessment
- room temperature
- cystic fibrosis
- rectal cancer
- drug induced
- structural basis